-
Mashup Score: 4
Results from the phase 3 KEYNOTE-826 trial show that the safety profile of pembrolizumab plus chemotherapy was manageable in cervical cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Objective response data from the CK-301-101 trial supports cosibelimab’s approval by the FDA, according to Jason J. Luke, MD, FACP.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Objective response data from the CK-301-101 trial supports cosibelimab’s approval by the FDA, according to Jason J. Luke, MD, FACP. #melsm | @jasonlukemd https://t.co/W8KBbo9MJf
-
-
Mashup Score: 2
Dostarlimab achieved a 100% clinical complete response rate in patients with dMMR/MSI-H advanced rectal cancer, a phase 2 study found.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Dostarlimab has been granted the breakthrough therapy designation by the FDA for the treatment of patients with locally advanced dMMR or MSI-H rectal cancer. #gicsm | @US_FDA @FDAOncology https://t.co/AFoDULtuCQ
-
-
Mashup Score: 0
Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians. #kicsm | @kidneycan @LisaHenske https://t.co/TBka14ji3d https://t.co/fCA7cFXXeN
-
-
Mashup Score: 2
Members of the panel discuss their criteria for determining when a patient is ready to transition back to community oncologists after they receive CAR T-cell therapy.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Members of the panel discuss their criteria for determining when a patient is ready to transition back to community oncologists after they receive CAR T-cell therapy. #mmsm | @szusmani @DoctorAKrishnan https://t.co/DVKsCKOHsk
-
-
Mashup Score: 0
The phase 3 CamRelief study reported a pathologic complete response rate of 56.8% for camrelizumab plus chemo compared with 44.7% for chemo alone.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
In all patients, the camrelizumab regimen elicited a pCR rate of 56.8% vs 44.7% with chemotherapy alone, translating to a 12.2% difference between the arms (95% CI, 3.3%-21.2%; 1-sided P = .0038). #bcsm #SABCS24 | @SABCSSanAntonio https://t.co/AfKg3EVa5e
-
-
Mashup Score: 0
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma. #lymsm #ASH24 | @ASH_hematology https://t.co/JkUPotEB4x
-
-
Mashup Score: 1
Meta-analysis data show moderate decreases in distant recurrence and breast cancer mortality with immediate surgery after longer follow-up.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Among 656 patients with node-negative disease, the rate of isolated local recurrence at 5 years was 45.4% for those who received tamoxifen alone vs 14.4% for tamoxifen plus surgery (RR, 0.19-0.34; P <.00001). #bcsm #SABCS24 | @SABCSSanAntonio https://t.co/f73hIO5Zb1
-
-
Mashup Score: 3Treating Patients Referred to Academic Centers for CAR T - 6 day(s) ago
Focusing on the transition of patients from community practices to academic centers, the panel discusses the initial evaluation and treatment processes, focusing on bridging therapy for patients awaiting CAR T.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Focusing on the transition of patients from community practices to academic centers, the panel discusses the initial evaluation and treatment processes, focusing on bridging therapy for patients awaiting CAR T. #mmsm | @DoctorAKrishnan @szusmani https://t.co/cUVf6IhfJG
-
-
Mashup Score: 1
Elascestrant with abemaciclib elicited an overall response rate of 18% in ER+/HER2– Breast Cancer, results from the 2 trials show.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
With a median follow-up of 7.5 months at data cutoff, efficacy-evaluable patients from the phase 1b portion of ELECTRA who received the doublet experienced a median PFS was 8.7 months (95% CI, 6.1-16.6). #SABCS24 | @SABCSSanAntonio @hoperugo https://t.co/KBKFmkSrMW
-
The median PFS in the pembrolizumab arm was 15.2 months (95% CI, 10.5-23.3) vs 10.2 months (95% CI, 8.3-12.2) in the placebo arm (HR, 0.57; 95% CI, 0.45-0.73). #gyncsm https://t.co/1gY1cyfvhT